Anti-Human CCL5 (Clone CPTC-CCL5-2) – Purified No Carrier Protein

CCL5 synthetic peptide EYFYTSGK

This monoclonal antibody is aseptically packaged and formulated in 0.01 M phosphate buffered saline (150 mM NaCl) PBS pH 7.2 - 7.4 with no carrier protein, potassium, calcium or preservatives added.

Liquid

Purified antibodies are manufactured in an animal free facility using only in vitro protein free cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates.

This antibody may be stored sterile as received at 2-8°C for up to one month. For longer term storage, aseptically aliquot in working volumes without diluting and store at ≤ -70°C. Avoid Repeated Freeze Thaw Cycles.

Research Use Only

2 – 8° C Wet Ice

FSAI157-2H5 activity is directed against CCL5 peptide sequence EYFYTSGK.

CPTC-CCL5-2

Chemotactic cytokines, along with their GPCR receptors, play important roles in regulating lymphoid tissue development, immune homeostasis, and inflammatory responses by directing leukocyte migration into injured or infected tissues¹. Additionally, chemokine signaling in the tumor microenvironment contributes to tumor cell proliferation, migration, invasion, angiogenesis, evasion, and resistance to immune checkpoint inhibitors.

CCL5 is an inflammatory chemokine that plays important roles in inflammation, immune response, antigen presentation, pathogen elimination, angiogenesis, and tumorigenesis². CCL5 controls immune cell migration and recruitment in basal and inflammatory environments. CCL5 functions by binding its receptors GPR75³, CCR1, CCR3, CCR4, and particularly CCR5, with which it functions in viral infection (HIV and Covid-19), inflammation and inflammatory disease, cancer progression, and immune response⁴. CCL5 has been proposed as a target of cancer immunotherapy and as a predictive biomarker for immune checkpoint inhibitor treatment². Other small molecule inhibitor strategies are also being investigated⁴.

FSAI157-2H5 was generated in mouse for use in immuno-MRM assay using a synthetic peptide derived from human CCL5, EYFYTSGK⁵. FSAI157-2H5 does not detect CCL5 by reverse phase protein array or Western blotting⁶.

https://antibodies.cancer.gov/detail/CPTC-CCL5-2#CPTC-CCL5-2

CCL5 is expressed by T cells, monocytes, epithelial cells, fibroblasts, thrombocytes, and natural killer cells.

CCR1, CCR3, CCR4, CCR5

1 Gao SH, Liu SZ, Wang GZ, et al. Life (Basel). 11(12):1282. 2021.
2 Shan J, Xu Y, Lun Y. Sci Rep. 14(1):22138. 2024.
3 Ignatov A, Robert J, Gregory-Evans C, et al. Br J Pharmacol. 149(5):490-497. 2006.
4 Zeng Z, Lan T, Wei Y, et al. Genes Dis. 9(1):12-27. 2022.
5 Whiteaker JR, Lundeen RA, Zhao L, et al. Front Immunol. 12:765898. 2021.
6 https://antibodies.cancer.gov/detail/CPTC-CCL5-2